CALR mutations are an important diagnostic marker in patients with suspected MPN which was recognized by the 2016 revision to the WHO classification of myeloid neoplasms and acute leukemia [16] which included CALR mutations as one of the major criteria for the diagnosis of ET and PMF. The gene discussed is CALR; the disease is essential thrombocythemia.